Company / Total Assets
Dianthus Therapeutics, Inc. /DE/ Total Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$530.9M
FY2025
5-year range
$83.1M / $530.9M
FY2021-FY2025
Trend
+42.0%
vs FY2024
Sector context
#132 of 214
Health Care
What the data says
At $531M, Dianthus Therapeutics, Inc. /DE/'s total assets ranks #132 of 214 in the Health Care sector. Total Assets has increased for 3 consecutive years, from $83M in FY2022 to $531M in FY2025.
Based on SEC 10-K filings.
$531M in FY2025 with a 5-year CAGR of +26.9%.
Improved from $179M to $531M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +85.5%
- 5-Year CAGR
- +26.9%
- 10-Year CAGR
- -
Sector benchmark
#132 of 214 in Health CareTop 62% of 214This company $530.9M Sector average $7.5B
▼
-92.9% below sector average
Key checks
Key Insights
- Dianthus Therapeutics, Inc. /DE/'s total assets has grown for 3 consecutive years.
- 5-year CAGR of +26.9%, indicating consistent growth.
- In FY2025, total assets increased 42.0% year-over-year.
- Ranks #132 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $530.9M | +42.0% |
| FY2024 | $374.0M | +108.5% |
| FY2023 | $179.4M | +115.9% |
| FY2022 | $83.1M | -56.2% |
| FY2021 | $189.9M | +17.5% |
| FY2020 | $161.6M | +0.1% |
| FY2019 | $161.5M | +2.7% |
| FY2018 | $157.3M | +188.8% |
| FY2017 | $54.5M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026